Treatment-emergent major adverse cardiovascular and thromboembolic events were infrequent during clinical trials of pegloticase
CV/TE event incidence during pegloticase treatment was similar to the general gout population (31.7 events/1000 person-years). These findings suggest that pegloticase initiation does not put patients at a higher risk for CV/TE events.
Authors
- K. Obermeyer
- Lissa Padnick‐Silver (ORCID: https://orcid.org/0000-0002-4199-4844)
- O. Troum (ORCID: https://orcid.org/0009-0005-3956-0253)
- Brian D. LaMoreaux (ORCID: https://orcid.org/0000-0001-7521-241X)
- Mai H. Duong (ORCID: https://orcid.org/0000-0002-6764-3233)
Institutions
- University of Southern California (US)
- Amgen (United States) (US)
- Providence College (US)
- Saint John's Health Center (US)
Publication Details
- Journal
- Lara D. Veeken
- Published
- 2025-01-10
- DOI
- https://doi.org/10.1093/rheumatology/keaf017
- Citations
- 1
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Amgen
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- Sanofi
- Horizon Therapeutics